JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients

 

 Buy Article Permissions and Reprints

Abstract

The objective of this study was to assess the risk of arterial thrombosis in patients who harbor the JAK2V617F allele burden ≥1% detected during workup for myeloproliferative neoplasms (MPNs). We conducted a large cross-sectional analysis consisted of 5,220 patients who were tested for JAK2V617F and 1,047,258 people matched in age from health care insurance provider, taking into account age, sex, hypertension, diabetes, atrial fibrillation. Compared with noncarriers, mutation carriers were older, less likely to be current or past smokers and had lower body mass index. There was no significant difference between the groups regarding myocardial infarction and peripheral vascular disease. However, JAK2V617F ≥1% at age 34 to 54 years was associated with eightfold more likely to have transient ischemic attack (TIA)/stroke history unrelated to hypertension, diabetes, or atrial fibrillation. Association of JAK2V617F with TIA/stroke was also observed in the older age group, albeit a weaker association and not statistically significant. Prevalence of TIA/stroke was higher in patients with JAK2V617F negative, with odds ratio of 3.93 when compared with the general population after confounder adjustments. Further research is warranted to verify the relation between allele burden of JAK2V617F mutation and TIA/stroke and the role of JAK2V617F per se as a risk factor for arterial thrombosis in the absence of overt MPN. Also, consideration should be paid to the screened group with JAK2V617F negative due to the high incidence of TIA/stroke among them in comparison to the general population.

Publication History

Received: 25 October 2021

Accepted: 14 January 2022

Article published online:
14 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 2013; 160 (01) 70-79
  CrossrefPubMedGoogle Scholar
• 2 Perricone M, Polverelli N, Martinelli G. et al. The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study. Oncotarget 2017; 8 (23) 37239-37249
  CrossrefPubMedGoogle Scholar
• 3 Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22 (01) 14-22
  CrossrefPubMedGoogle Scholar
• 4 Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells 2019; 8 (08) 854
  CrossrefPubMedGoogle Scholar
• 5 Vassiliou GS. JAK2 V617F clonal disorders: fate or chance?. Blood 2016; 128 (08) 1032-1033
  CrossrefPubMedGoogle Scholar
• 6 Steensma DP, Bejar R, Jaiswal S. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126 (01) 9-16
  CrossrefPubMedGoogle Scholar
• 7 Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HLA, Leebeek FWG. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120 (25) 4921-4928
  CrossrefPubMedGoogle Scholar
• 8 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5 (04) 708-714
  CrossrefPubMedGoogle Scholar
• 9 Pardanani A, Lasho TL, Hussein K. et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83 (04) 457-459
  CrossrefPubMedGoogle Scholar
• 10 Hultcrantz M, Björkholm M, Dickman PW. et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 2018; 168 (05) 317-325
  CrossrefPubMedGoogle Scholar
• 11 Bench AJ, White HE, Foroni L. et al; British Committee for Standards in Haematology. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol 2013; 160 (01) 25-34
  CrossrefPubMedGoogle Scholar
• 12 Passamonti F, Rumi E, Pietra D. et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107 (09) 3676-3682
  CrossrefPubMedGoogle Scholar
• 13 Barbui T, Finazzi G, Carobbio A. et al. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (26) 5128-5133 , quiz 5252
  CrossrefPubMedGoogle Scholar
• 14 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017; 92 (01) 94-108
  CrossrefPubMedGoogle Scholar
• 15 Barbui T. What is the standard treatment in essential thrombocythemia. Int J Hematol 2002; 76 (Suppl. 02) 311-317
  CrossrefPubMedGoogle Scholar
• 16 Košťál M, Schwarz J, Ovesná P, Penka M, Dulíček P. for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms. Ph^- myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide. J Thromb Thrombolysis 2021; 51 (01) 112-119
  CrossrefPubMedGoogle Scholar
• 17 Nagai K, Shimoyama T, Yamaguchi H. et al. Clinical characteristics and brain MRI findings in myeloproliferative neoplasms. J Neurol Sci 2020; 416: 116990
  CrossrefPubMedGoogle Scholar
• 18 Edelmann B, Gupta N, Schnoeder TM. et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest 2018; 128 (10) 4359-4371
  CrossrefPubMedGoogle Scholar
• 19 Guadall A, Lesteven E, Letort G. et al. Endothelial cells harbouring the JAK2^V617F mutation display pro-adherent and pro-thrombotic features. Thromb Haemost 2018; 118 (09) 1586-1599
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Guy A, Gourdou-latyszenok V, Le Lay N. et al. Vascular endothelial cell expression of JAK2^V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica 2019; 104: 70-81
  CrossrefPubMedGoogle Scholar
• 21 Zhu H, Jian Z, Zhong Y. et al. Janus Kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition. Front Immunol 2021; 12: 714943
  CrossrefPubMedGoogle Scholar
• 22 Mannucci M, Peyvandi F. Thrombophilia screening: little role for the JAK2V617F mutation. Mayo Clin Proc 2008; 83: 398-399
  CrossrefPubMedGoogle Scholar
• 23 Remacha AF, Estivill C, Sarda MP. et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285-286
  CrossrefPubMedGoogle Scholar
• 24 Landolfi R, Di Gennaro L, Nicolazzi MA, Giarretta I, Marfisi RM, Marchioli R. Polycythemia vera: gender-related phenotype differences. Intern Emerg Med 2012; 7: 509-512
  CrossrefPubMedGoogle Scholar
• 25 Klampfl T, Gisslinger H, Harutyunyan AS. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390
  CrossrefPubMedGoogle Scholar
• 26 De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost 2016; 115: 240-249
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis 2011; 2011: 874146
  CrossrefPubMedGoogle Scholar
• 28 Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol 2002; 118: 1071-1077
  CrossrefPubMedGoogle Scholar
• 29 Colaizzo D, Tiscia GL, Bafunno V. et al. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. Thromb Res 2011; 128: 233-236
  CrossrefPubMedGoogle Scholar
• 30 Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 2021; 35: 3339-3351
  CrossrefPubMedGoogle Scholar
• 31 Carobbio A, Finazzi G, Antonioli E. et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 2009; 37: 1016-1021
  CrossrefPubMedGoogle Scholar